ReST Therapeutics is an early-stage, biotech company originally founded in 2020 in Paris, France, now located in New Haven, CT.  ReST is developing transformative therapies for patients with significant, unmet needs in Psychiatry and Neurodegeneration.

With our lead program, RST-01, we intend to disrupt the existing PTSD treatment paradigm by focusing on early intervention, immediately following a traumatic event and a patient-centric clinical development strategy. RST-01 is unique in that it selectively targets the NMDA receptors in the brain which are critical to memory consolidation. Pre-clinical testing has shown drastic reductions in fear, anxiety and depression with RST-01.

Beyond psychiatry, NMDAR selective modulation has demonstrated outstanding results in Alzheimer models, the cognitive function being integrally restored and amyloid put under control through glial cells activity, opening the door to the development of a suite of assets to restore the quality of lives of those affected by debilitating neurodegenerative diseases, particularly ALS and AD.

Medtronic develops and manufactures devices and therapies to treat more than 30 chronic diseases, including heart failure, Parkinson disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders and diabetes.

Alert Scientific, Inc., an ISO/IEC 17025 Accredited Company, in business since 1986, provides specialized service on hundreds of different types of laboratory equipment; as well as factory-authorized repair, preventive maintenance and calibration, and validation in the form of IQ/OQ/PQ. We repair and perform NSF Accredited Certification on bio-safety cabinets, chemical fume hoods, laminar flow hoods and clean rooms. Our calibration and test equipment are NIST traceable. We offer Rental Freezers and White Glove Deliveries within our service area.

Please visit our website for additional information and use our Contact Us page to initiate service requests or to inquire about any of our services

Growth. Value. Managing risk. Regardless of how you define it, success in today’s global market means addressing increasingly complex issues faster and more efficiently amid rapid change. Making the right decisions in this environment requires strategic legal counsel from advisors who not only know how laws are evolving but have a deep understanding of how to align legal strategy with commercial objectives. This is Nutter.

Nutter’s life science team, which includes multiple PhDs in various disciplines, knows how critical it is to understand a client’s business and the unique pressures driving it. Our experience runs deep—whether small or large molecules or diagnostics—our life science lawyers tackle matters concerning complex patent prosecution and freedom to operate, licensing and agreements; research and development funding; clinical trial strategy; and FDA safe harbor advice. Clients turn to us for legal counsel throughout all stages of their lifecycle, whether it is the opportunity to collaborate or partner with industry leaders, pursue mission-critical patent protection, or prepare for an initial public offering or a merger/acquisition. By applying our wealth of expertise in biology, chemistry, and related life science technologies, we help transform our clients’ ideas and goals into business strategies and products.

Renovo Life Sciences is passionate about creating Asset and Laboratory Management Solutions that are driven by innovation, transparency, sustainability, and a focus on unbiased results. We provide a single – source Lab Asset Management Solution providing Inventory Management, Asset Utilization, PM scheduling, Calibration and Laboratory Relocation Services.

Renovo’s systematic tracking, organization, and maintenance of your lab equipment, instruments, and resources ensures that our clients can expect improved operational efficiencies that lead to greater asset uptime while reducing inventory costs This, in turn, gives time back to the scientists to focus on science – a win-win solution!

Our mission is enabling our partners with solutions that ensure the quality and speed of science.

Ancora invests in real estate at the heart of innovation. A partnership of Ancora Real Estate Holdings LLC., and Legal & General Capital, Ancora is a vertically integrated investor, developer, and operator of life sciences, research, and mixed-use real estate. Our work sits at the intersection of commercial real estate and the educational, healthcare, R&D and commercialization demands that drive higher education and medical institutions. These anchor institutions must manage disruption, recalibration, and innovation as powerful shifts – demographic, economic, and digital – shape faculty recruitment and student enrollment, finance, research funding, and relationships with neighboring communities and governments. We understand these ongoing dynamics, and craft real estate approaches that echo and enhance each institution’s place and direction. For leaders who recognize and act, these changes present opportunities that can bring broad benefits.

AVS Bio is the worlds largest producer of Specific Pathogen Free (SPF) eggs as well as laboratory products and services for the development and manufacture of Biologics.  We are establishing a research group to expand our new product offerings across both human and animal health markets.

Research Activities:

The research team is working on development of new products for the human and animal health markets.  One of our current projects is working on new IgY antibody products using SPF chicken eggs.

Alpha-1 Foundation is dedicated to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide.

Research Activities:

We have invested more than $97 million into Alpha-1 research and related programs. Some twenty biotechs have drug development programs in progress of which one half are in clinical trial. About six are gene based interventions.

The National Organization for Rare Disorders (NORD) is a 501(c)(3) patient advocacy organization that improves the health and well-being of patients living with rare diseases by improving care, accelerating research, and driving public policy. Our Corporate Council comprises over a hundred biopharmaceutical companies, clinical research organizations, and other stakeholders involved in the drug development process for orphan treatments. NORD’s membership includes more than 340 patient advocacy organizations and 40+ Rare Disease Centers of Excellence, including Yale New Haven Hospital.

NORD’s headquarters are in Danbury, CT, and satellite offices are in Quincy, Massachusetts, and Washington, D.C.

Research Activities:

NORD is a leader in patient-focused drug development (PFDD) on behalf of the rare disease community. Through our medical affairs and research teams, and in partnership with patient advocacy groups and regulatory bodies, we are accelerating research for rare diseases through the following mechanisms:

– NORD brings together teams of clinical experts in a nationwide network of cutting-edge facilities, with the goal to provide standards of specialized care and disease management for people living with rare disease and their families

– Our IAMRARE® program helps researchers to develop and conduct natural history studies and patient registries on our platform that is designed to collect disease-specific and disease-agnostic patient experience data in multiple languages.

– We provide seed grants for academic scientists to pursue studies related to the development of potential new diagnostics or treatments in order to provide preliminary data and attract funding from government or industry sponsors.

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies; and technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here.